GlaxoSmithKline Pharmaceuticals Limited — Important, 03-06-2025: Updates

GlaxoSmithKline Pharmaceuticals strengthened its ESG profile with a 3.3% cut in water use and Zero Liquid Discharge at the Nashik plant. The respiratory portfolio expanded with Trelegy and Nucala auto-injectors, alongside a successful multi-specialty launch of the Shingrix vaccine. Mental wellbeing programs and employee safety training were prioritized. CSR efforts reached over 41,400 marginalized individuals. Operational efficiency and patient-focused product delivery remain core, with no fines or penalties reported and high complaint resolution rates.